ClinicalTrials.gg
CompletedNCT04191616SELECTUpdated Sep 4, 2025Results posted

Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet

A Phase 2 interventional study of Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma, sponsored by Amgen. Completed at 46 sites in 8 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2025-09-04.

Primary conditionMultiple MyelomaRegistry: RecurrenceReclassifiedWhy we changed it
Registry
Recurrence — the first condition term the registry derived for this study.
ClinicalTrials.gg
Multiple Myeloma
Why
  1. Recurrence describes something many studies share rather than a condition a study is about.
  2. The study's listed conditions name Multiple Myeloma.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Amgen · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
54
Allocation
Not applicable
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 113 studies testing carfilzomib in Multiple Myeloma — 14 open to participants now, 39 under way, 7 of them phase 3. carfilzomib · Multiple Myeloma.

Enrollment
56th of 113
54 · median 54
Started
2020
with 5 others
Phase 2
50 of 113
6 open now
Registered
87th of 113
by date
Lead sponsor
21 of 113
Amgen

Among the 113 studies testing carfilzomib in Multiple Myeloma, this one is the 56th largest by enrollment, is one of 6 that started in 2020, is one of 50 in phase 2, and was the 87th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

14 of the 113 studies testing carfilzomib in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About carfilzomib

carfilzomib: first FDA approval 2012 (KYPROLIS), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 113 studies testing carfilzomib in Multiple Myeloma, or all of them as a file.
02

Study summary

A Study Evaluating Treatment of Multiple Myeloma with Carfilzomib in Combination with Pomalidomide and Dexamethasone

Read the detailed description

An Open-label, Phase 2 Study Treating Subjects with First or Second Relapse of Multiple Myeloma with Carfilzomib, Pomalidomide, and Dexamethasone (KPd)

This trial is designed to estimate the efficacy of a carfilzomib-based triplet in first or second relapse of multiple myeloma for subjects refractory to lenalidomide. The study is an open-label, phase 2 trial. Subjects may receive treatment until progression.

Myeloma disease status will be monitored locally for response and progression per International Myeloma Working Group (IMWG) criteria (Kumar et al, 2016) every 28 ± 7 days from cycle 1 day 1 until confirmed progressive disease (PD), death, lost to follow-up, or withdrawal of full consent (whichever occurs first), regardless of cycle duration, dose delays or treatment discontinuation. Subjects with a suspected complete response (CR) or better will have a bone marrow for minimal residual disease (MRD) assessment at 12 and 24 months (± 4 weeks) from start of treatment (unless a MRD assessment was performed within 4 months before planned assessment).

Subjects who end study drug(s) without confirmed PD are required to complete disease response assessments and report new anti-myeloma treatment every 28 ± 7 days until first subsequent anti-myeloma treatment, death, lost to follow-up, withdrawal of full consent, confirmed PD, or end of study, whichever occurs first. Subjects who discontinue treatment and either start new anti-myeloma treatment or have PD will enter long-term follow-up every 12 weeks until death or end of study.

Approximately one-third of subjects enrolled in the study will be in first relapse and two-thirds in second relapse.

This study will enroll adults ≥ 18 years of age with first or second relapse multiple myeloma.

Eligible subjects will have relapsed multiple myeloma after receiving 1 or 2 prior lines of therapy.

Subjects must be refractory to lenalidomide. Subjects may not have received prior pomalidomide. Prior exposure to a proteasome inhibitor is allowed. Subjects previously exposed to carfilzomib must have responded with at least a partial response to carfilzomib, must not have discontinued carfilzomib due to toxicity, may not have relapsed while receiving or within 60 days of the last dose of carfilzomib, and must have at least a 6 month carfilzomib treatment-free interval since their last dose of carfilzomib.

Subjects must have measurable disease per IMWG consensus criteria, Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 2, and at least partial response to 1 line of therapy.

03

Conditions studied

  • Relapsed or Refractory Multiple Myeloma

Browse trials for

Keywords

  • Multiple Myeloma
  • RRMM
  • Open-label
  • First Relapse Multiple Myeloma
  • Second Relapse Multiple Myeloma
  • Refractory to Lenalidomide
  • Triplicate Treatment Regimen
  • Dexamethasone
  • Carfilzomib
  • Pomalidomide
04

In context

Multiple Myeloma Reclassified

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

This study's enrollment of 54 is above the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.

Browse Multiple Myeloma studies →

Lead sponsor

Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.

Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.

Compared within Multiple Myeloma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject has provided prior to initiation of any study specific activities or procedures.
  • Male or female subjects age ≥ 18 years
  • First or second relapse of multiple myeloma by IMWG criteria (subjects to the most recent , excluding carfilzomib, are eligible)
  • Refractory to lenalidamide
  • with at least 1 of the following assessed within 28 days prior to enrollment:

    • IgG multiple myeloma: serum monoclonal protein (M-protein) level ≥ 1.0 g/dL
    • IgA, IgD, IgE multiple myeloma: serum M-protein level ≥ 0.5 g/dL
    • urine M-protein ≥ 200 mg per 24 hours
    • in subjects without measurable serum or urine M-protein, serum-free light chain (SFLC) ≥ 100 mg/L (involved light chain) and an abnormal serum kappa lambda ratio
  • Must have at least a PR to at least 1 line of prior therapy
  • Prior therapy with proteasome inhibitors is allowed. Subjects receiving prior carfilzomib therapy must have achieved at least a PR, was not removed due to toxicity, did not relapse within 60 days from discontinuation of carfilzomib, and must have at least a 6 month carfilzomib treatment-free interval from their last dose of carfilzomib
  • PS of 0 to 2

Exclusion criteria

Exclusion Criteria

  • Primary multiple myeloma
  • Waldenström macroglobulinemia
  • Multiple myeloma of IgM subtype
  • POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes)
  • Plasma cell leukemia ( greater than 2.0 × 109/L circulating plasma cells by differential). If automated differential shows ≥ 20% of other cells, obtain manual differential to identify other cells.
  • Primary amyloidosis (patients with multiple myeloma with asymptomatic deposition of amyloid plaques found on would be eligible if all other criteria are met)
  • Previous diagnosis of amyloidosis associated with myeloma
  • Myelodysplastic syndrome
  • Toxicity requiring discontinuation of lenalidomide therapy
  • Prior treatment with pomalidomide
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
54 participants (actual)

Study arms

  • Experimental
    Carfilzomib combined with pomalidomide and dexamethasone

    Carfilzomib, pomalidomide, and dexamethasone (KPd)

    Drug: Carfilzomib · Drug: Dexamethasone · Drug: Pomalidomide

Interventions

  • Carfilzomib will be administered intravenously over 30 ± 5 minutes, on days 1, 8, and 15 (± 2 days) of each 28-day cycle for up to 12 cycles or progression. A dose of 20 mg/m\^2 will be administered on day 1 of cycle 1. All subsequent doses will be 56 mg/m\^2. The frequency of carfilzomib administration will be reduced to day 1 and 15 per cycle starting with cycle 13 and continued until progression or end of study.

    Also known as: Kyprolis

  • Dexamethasone will be administered at least 30 minutes, but no more than 4 hours prior to carfilzomib on days of carfilzomib administration. Dexamethasone will be administered at a dose of 40 mg on days 1, 8, 15, and 22 of each 28-day cycle up to progression during cycles 1 to 12. Dexamethasone will be administered at a dose of 20 mg on days 1 and 15 of each 28-day cycle up to progression during cycles 13 onward. For subjects more than or equal to 75 years of age, the dose will be 20 mg during cycles 1 through 12 and 10 mg from cycles 13 onward.

    Also known as: Decadron, Ozurdex, DexPak 6, 10, 13 Day, ReadySHarp, LoCort, Maxidex

  • Pomalidomide dose will be 4 mg per day orally on days 1 to 21 of each cycle until progression.

    Also known as: Pomalyst

07

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR) As Assessed by the Independent Review Committee (IRC)

    Overall response was defined as the best overall confirmed response of: Complete response (CR): Negative immunofixation on serum and urine, soft tissue plasmacytomas disappearance, \< 5% plasma cells in bone marrow (BM). Stringent CR (sCR): CR and normal serum free light chain ratio and no clonal cells in BM. Very Good Partial Response (VGPR): Serum and urine M-protein detectable by immunofixation or ≥ 90% reduction in serum M-protein (urine M-protein level \< 100 mg/24-h). PR: ≥ 50% reduction of serum M-protein and 24-h urinary M-protein by ≥ 90% or to \< 200 mg/24-h. Assessment was by IRC per International Myeloma Working Group Uniform Response Criteria (IMWG-URC). The 90% confidence intervals were estimated using the Clopper-Pearson method (1994).

    Time frame: From day 1 cycle 1 until the primary analysis (PA) data cutoff (DCO); the mean duration of KPd treatment as of the DCO was 42.0 weeks

Secondary outcomes

  1. Percentage of Participants With a Minimal Residual Disease Negative Complete Response (MRD[-]CR) as Assessed by the IRC

    The MRD\[-\]CR rate was defined as the percentage of participants who reached MRD\[-\]CR at the 12 month landmark (8- to 13-month window). MRD\[-\]CR was defined as the achievement of CR (including sCR or better) per IMWG-URC by IRC assessment and MRD\[-\] status at a sensitivity of 10\^-5 using next-generation sequencing based method in the bone marrow. The 90% CIs were estimated using the Clopper-Pearson method (1994).

    Time frame: Day 1 cycle 1 to month 12 (8 to 13 month window)

  2. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    TEAEs were defined as events with onset on or after the administration of the first dose of any study treatment and within the end of study, or 30 days after the last dose of any study treatment, whichever one was earlier, excluding events reported after end of study date.

    Time frame: From the first dose of any study treatment until the end of study or 30 days after the last dose of any study treatment, whichever occured earlier; Median (min, max) was 8.5 (1.0, 46.6) months

  3. Number of Participants Achieving MRD[-] Response

    MRD\[-\] response was defined as achievement of MRD\[-\] status using next generation sequencing (NGS) based method in the bone marrow at any time.

    Time frame: From day 1 cycle 1 until the end of study (EOS); the mean duration of KPd treatment as of the EOS was 55.3 weeks

  4. Number of Participants With Sustained MRD[-]CR for at Least 12 Months as Assessed by the IRC

    MRD\[-\]CR at the 12 months landmark was defined as achievement of CR (including sCR or better) per IMWG-URC by IRC and MRD\[-\] status at a sensitivity of 10\^-5 using NGS based method in the bone marrow at the 12 months landmark (from 8 months to 13 months window). Maintaining MRD\[-\]CR for at least 12 months (- 4 weeks) was considered as sustained.

    Time frame: Day 1 cycle 1 to month 12 (8 to 13 month window)

  5. Number of Participants With Sustained MRD[-]CR at Month 24 as Assessed by the IRC

    Sustained MRD\[-\]CR at 24 months included participants that maintained MRD\[-\]CR for 12 months or more after achieving MRD\[-\]CR status at 12 months.

    Time frame: Day 1 cycle 1 to month 26 (19 to 26 month window)

  6. Kaplan-Meier Estimate of Duration of Response as Assessed by the IRC

    Disease response and progression were determined using IMWG-URC. Durations were calculated for responders. Medians and percentiles were estimated using the Kaplan-Meier method. 90% CIs for medians and percentiles were estimated using the method by Klein and Moeschberger (1997) with log-log transformation.

    Time frame: From day 1 cycle 1 until the PA DCO; the mean duration of KPd treatment as of the DCO was 42.0 weeks

  7. Time to Response as Assessed by the IRC

    Durations were calculated for responders. Time to response was defined as the time from start of any study treatment date to the earliest date when confirmed sCR, CR, very good partial response (VGPR), or partial response (PR) was first achieved.

    Time frame: From day 1 cycle 1 until the PA DCO; the mean duration of KPd treatment as of the DCO was 42.0 weeks

  8. Kaplan-Meier Estimate of Progression Free Survival (PFS) as Assessed by the IRC

    PFS was defined as time from start of treatment until progression or death from any cause. Medians and percentiles were estimated using the Kaplan-Meier method by Klein and Moeschberger (1997). 90% CIs for medians were estimated using the method by Klein and Moeschberger (1997) with log-log transformation.

    Time frame: From day 1 cycle 1 until the PA DCO; the mean duration of KPd treatment as of the DCO was 42.0 weeks

  9. Kaplan-Meier Estimate of Overall Survival (OS)

    OS was defined as the time from the start of treatment until death from any cause. Medians and percentiles were estimated using the Kaplan-Meier method. 90% CIs for medians were estimated using the method by Klein and Moeschberger (1997) with log-log transformation.

    Time frame: From day 1 cycle 1 until the EOS; the mean duration of KPd treatment was 55.3 weeks.

  10. Number of Participants With Best Overall Confirmed Response of CR or Better as Assessed by the IRC

    The number of safety analysis set participants whose best overall response was sCR or CR per IMWG-URC over the duration of the study.

    Time frame: From day 1 cycle 1 until the PA DCO; the mean duration of KPd treatment as of the DCO was 42.0 weeks

08

Results

Posted Nov 8, 2023

Participant flow

Participants were enrolled at 25 study centers in Denmark, France, Germany, Greece, Italy, Spain, and the United States from 06 August 2020 to 01 October 2024.

Pre-assignment Period
Participant flow — Pre-assignment Period
MilestoneCarfilzomib With Pomalidomide and Dexamethasone (KPd)
Started54
Completed52
Not completed2
Withdrew: Did not receive study treatment2
Treatment Period
Participant flow — Treatment Period
MilestoneCarfilzomib With Pomalidomide and Dexamethasone (KPd)
Started52
Received carfilzomib52
Received pomalidomide52
Received dexamethasone52
Completed0
Not completed52
Withdrew: Death37
Withdrew: Sponsor decision11
Withdrew: Withdrawal by subject4

Outcome measures

PrimaryOverall Response Rate (ORR) As Assessed by the Independent Review Committee (IRC)

Overall response was defined as the best overall confirmed response of: Complete response (CR): Negative immunofixation on serum and urine, soft tissue plasmacytomas disappearance, \< 5% plasma cells in bone marrow (BM). Stringent CR (sCR): CR and normal serum free light chain ratio and no clonal cells in BM. Very Good Partial Response (VGPR): Serum and urine M-protein detectable by immunofixation or ≥ 90% reduction in serum M-protein (urine M-protein level \< 100 mg/24-h). PR: ≥ 50% reduction of serum M-protein and 24-h urinary M-protein by ≥ 90% or to \< 200 mg/24-h. Assessment was by IRC per International Myeloma Working Group Uniform Response Criteria (IMWG-URC). The 90% confidence intervals were estimated using the Clopper-Pearson method (1994).

Time frame:
From day 1 cycle 1 until the primary analysis (PA) data cutoff (DCO); the mean duration of KPd treatment as of the DCO was 42.0 weeks
Reported as:
Number · percentage of participants
Overall Response Rate (ORR) As Assessed by the Independent Review Committee (IRC)
percentage of participantsCarfilzomib With Pomalidomide and Dexamethasone (KPd)
Overall Response Rate (ORR) As Assessed by the Independent Review Committee (IRC)57.7 (45.4 to 69.3)
SecondaryPercentage of Participants With a Minimal Residual Disease Negative Complete Response (MRD[-]CR) as Assessed by the IRC

The MRD\[-\]CR rate was defined as the percentage of participants who reached MRD\[-\]CR at the 12 month landmark (8- to 13-month window). MRD\[-\]CR was defined as the achievement of CR (including sCR or better) per IMWG-URC by IRC assessment and MRD\[-\] status at a sensitivity of 10\^-5 using next-generation sequencing based method in the bone marrow. The 90% CIs were estimated using the Clopper-Pearson method (1994).

Time frame:
Day 1 cycle 1 to month 12 (8 to 13 month window)
Reported as:
Number · percentage of participants
Percentage of Participants With a Minimal Residual Disease Negative Complete Response (MRD[-]CR) as Assessed by the IRC
percentage of participantsCarfilzomib With Pomalidomide and Dexamethasone (KPd)
Percentage of Participants With a Minimal Residual Disease Negative Complete Response (MRD[-]CR) as Assessed by the IRC3.8 (0.7 to 11.6)
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs)

TEAEs were defined as events with onset on or after the administration of the first dose of any study treatment and within the end of study, or 30 days after the last dose of any study treatment, whichever one was earlier, excluding events reported after end of study date.

Time frame:
From the first dose of any study treatment until the end of study or 30 days after the last dose of any study treatment, whichever occured earlier; Median (min, max) was 8.5 (1.0, 46.6) months
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsCarfilzomib With Pomalidomide and Dexamethasone (KPd)
Number of Participants With Treatment-emergent Adverse Events (TEAEs)50
SecondaryNumber of Participants Achieving MRD[-] Response

MRD\[-\] response was defined as achievement of MRD\[-\] status using next generation sequencing (NGS) based method in the bone marrow at any time.

Time frame:
From day 1 cycle 1 until the end of study (EOS); the mean duration of KPd treatment as of the EOS was 55.3 weeks
Reported as:
Count of participants · Participants
Number of Participants Achieving MRD[-] Response
ParticipantsCarfilzomib With Pomalidomide and Dexamethasone (KPd)
Number of Participants Achieving MRD[-] Response5
SecondaryNumber of Participants With Sustained MRD[-]CR for at Least 12 Months as Assessed by the IRC

MRD\[-\]CR at the 12 months landmark was defined as achievement of CR (including sCR or better) per IMWG-URC by IRC and MRD\[-\] status at a sensitivity of 10\^-5 using NGS based method in the bone marrow at the 12 months landmark (from 8 months to 13 months window). Maintaining MRD\[-\]CR for at least 12 months (- 4 weeks) was considered as sustained.

Time frame:
Day 1 cycle 1 to month 12 (8 to 13 month window)
Reported as:
Count of participants · Participants
Number of Participants With Sustained MRD[-]CR for at Least 12 Months as Assessed by the IRC
ParticipantsCarfilzomib With Pomalidomide and Dexamethasone (KPd)
Number of Participants With Sustained MRD[-]CR for at Least 12 Months as Assessed by the IRC0
SecondaryNumber of Participants With Sustained MRD[-]CR at Month 24 as Assessed by the IRC

Sustained MRD\[-\]CR at 24 months included participants that maintained MRD\[-\]CR for 12 months or more after achieving MRD\[-\]CR status at 12 months.

Time frame:
Day 1 cycle 1 to month 26 (19 to 26 month window)
Reported as:
Count of participants · Participants
Number of Participants With Sustained MRD[-]CR at Month 24 as Assessed by the IRC
ParticipantsCarfilzomib With Pomalidomide and Dexamethasone (KPd)
Number of Participants With Sustained MRD[-]CR at Month 24 as Assessed by the IRC0
SecondaryKaplan-Meier Estimate of Duration of Response as Assessed by the IRC

Disease response and progression were determined using IMWG-URC. Durations were calculated for responders. Medians and percentiles were estimated using the Kaplan-Meier method. 90% CIs for medians and percentiles were estimated using the method by Klein and Moeschberger (1997) with log-log transformation.

Time frame:
From day 1 cycle 1 until the PA DCO; the mean duration of KPd treatment as of the DCO was 42.0 weeks
Reported as:
Median · months
Kaplan-Meier Estimate of Duration of Response as Assessed by the IRC
monthsCarfilzomib With Pomalidomide and Dexamethasone (KPd)
Kaplan-Meier Estimate of Duration of Response as Assessed by the IRC20.3 (9.2 to NA)
SecondaryTime to Response as Assessed by the IRC

Durations were calculated for responders. Time to response was defined as the time from start of any study treatment date to the earliest date when confirmed sCR, CR, very good partial response (VGPR), or partial response (PR) was first achieved.

Time frame:
From day 1 cycle 1 until the PA DCO; the mean duration of KPd treatment as of the DCO was 42.0 weeks
Reported as:
Median · months
Time to Response as Assessed by the IRC
monthsCarfilzomib With Pomalidomide and Dexamethasone (KPd)
Time to Response as Assessed by the IRC1.0 (1 to 2)
SecondaryKaplan-Meier Estimate of Progression Free Survival (PFS) as Assessed by the IRC

PFS was defined as time from start of treatment until progression or death from any cause. Medians and percentiles were estimated using the Kaplan-Meier method by Klein and Moeschberger (1997). 90% CIs for medians were estimated using the method by Klein and Moeschberger (1997) with log-log transformation.

Time frame:
From day 1 cycle 1 until the PA DCO; the mean duration of KPd treatment as of the DCO was 42.0 weeks
Reported as:
Median · months
Kaplan-Meier Estimate of Progression Free Survival (PFS) as Assessed by the IRC
monthsCarfilzomib With Pomalidomide and Dexamethasone (KPd)
Kaplan-Meier Estimate of Progression Free Survival (PFS) as Assessed by the IRC11.1 (6.5 to NA)
SecondaryKaplan-Meier Estimate of Overall Survival (OS)

OS was defined as the time from the start of treatment until death from any cause. Medians and percentiles were estimated using the Kaplan-Meier method. 90% CIs for medians were estimated using the method by Klein and Moeschberger (1997) with log-log transformation.

Time frame:
From day 1 cycle 1 until the EOS; the mean duration of KPd treatment was 55.3 weeks.
Reported as:
Median · months
Kaplan-Meier Estimate of Overall Survival (OS)
monthsCarfilzomib With Pomalidomide and Dexamethasone (KPd)
Kaplan-Meier Estimate of Overall Survival (OS)17.6 (11.2 to 23.5)
SecondaryNumber of Participants With Best Overall Confirmed Response of CR or Better as Assessed by the IRC

The number of safety analysis set participants whose best overall response was sCR or CR per IMWG-URC over the duration of the study.

Time frame:
From day 1 cycle 1 until the PA DCO; the mean duration of KPd treatment as of the DCO was 42.0 weeks
Reported as:
Count of participants · Participants
Number of Participants With Best Overall Confirmed Response of CR or Better as Assessed by the IRC
ParticipantsCarfilzomib With Pomalidomide and Dexamethasone (KPd)
Number of Participants With Best Overall Confirmed Response of CR or Better as Assessed by the IRC3

Adverse events

Collected over All-cause mortality: from enrollment until the end of study or death date, whichever occurs later; Median (min, max) time on study was 15.2 (0.0, 47.0) months. Adverse events: from the first dose of any study treatment until the end of study or 30 days after the last dose of any study treatment, whichever occurs earlier; Median (min, max) was 8.5 (1.0, 46.6) months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Carfilzomib With Pomalidomide and Dexamethasone (KPd)37/54 (68.5%)22/52 (42.3%)48/52 (92.3%)
Most frequent serious events
Showing 10 of 28
Most frequent serious events
EventCarfilzomib With Pomalidomide and Dexamethasone (KPd)
Acute kidney injuryRenal and urinary disorders3/52
Respiratory failureRespiratory, thoracic and mediastinal disorders3/52
NeutropeniaBlood and lymphatic system disorders2/52
COVID-19Infections and infestations2/52
COVID-19 pneumoniaInfections and infestations2/52
InfectionInfections and infestations2/52
PneumoniaInfections and infestations2/52
SepsisInfections and infestations2/52
Cerebrovascular accidentNervous system disorders2/52
LeukopeniaBlood and lymphatic system disorders1/52
Most frequent other events
Showing 10 of 33
Most frequent other events
EventCarfilzomib With Pomalidomide and Dexamethasone (KPd)
NeutropeniaBlood and lymphatic system disorders17/52
AnaemiaBlood and lymphatic system disorders16/52
ThrombocytopeniaBlood and lymphatic system disorders16/52
FatigueGeneral disorders12/52
Oedema peripheralGeneral disorders11/52
DiarrhoeaGastrointestinal disorders9/52
AstheniaGeneral disorders9/52
PyrexiaGeneral disorders8/52
DyspnoeaRespiratory, thoracic and mediastinal disorders8/52
RashSkin and subcutaneous tissue disorders8/52

Baseline characteristics

Baseline measures are presented for the safety analysis set which included participants who received at least 1 dose of carfilzomib.

Age, Continuous
Age, Continuous(years)Carfilzomib With Pomalidomide and Dexamethasone (KPd)
Mean66.2 ± 9.4
Sex: Female, Male
Sex: Female, Male(Participants)Carfilzomib With Pomalidomide and Dexamethasone (KPd)
Female28
Male24
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Carfilzomib With Pomalidomide and Dexamethasone (KPd)
Hispanic or Latino4
Not Hispanic or Latino45
Unknown or Not Reported3
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Carfilzomib With Pomalidomide and Dexamethasone (KPd)
Asian1
Black or African American1
White47
Other3
09

Study locations

46 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35249, United States
  • Rocky Mountain Cancer Centers Denver Midtown
    Denver, Colorado 80218, United States
  • Yale Cancer Center
    New Haven, Connecticut 06510, United States
  • Affiliated Oncologists, LLC
    Chicago Ridge, Illinois 60415, United States
  • Minnesota Oncology Hematology PA
    Saint Paul, Minnesota 55102, United States
  • Oncology Hematology Care Incorporated
    Cincinnati, Ohio 45236, United States
  • Texas Oncology - Austin Midtown
    Austin, Texas 78705, United States
  • United States Oncology Regulatory Affairs Corporate Office
    Austin, Texas 78705, United States
  • US Oncology Research Investigational Products Center
    Austin, Texas 78705, United States
  • Baylor Charles A Sammons Cancer Center at Dallas
    Dallas, Texas 75246, United States
  • Texas Oncology, Fort Worth
    Fort Worth, Texas 76104, United States
  • Texas Oncology- Tyler
    Tyler, Texas 75702, United States
  • Blue Ridge Cancer Care
    Roanoke, Virginia 24014, United States
  • Aalborg Universitetshospital
    Aalborg, 9000, Denmark
  • Aarhus Universitetshospital
    Aarhus N, 8200, Denmark
  • Sjaellands Universitetshospital
    Roskilde, 4000, Denmark
  • Vejle Sygehus
    Vejle, 7100, Denmark
  • North Estonia Medical Centre
    Tallinn, 13419, Estonia
  • CHU Grenoble Alpes
    Grenoble, 38043, France
  • Centre Hospitalier Régional Universitaire de Lille - Hôpital Claude Huriez
    Lille, 59037, France
  • Centre Hospitalier Universitaire de Nantes
    Nantes, 44093, France
  • Centre Hospitalier Universitaire de Bordeaux - Hôpital Haut Lévêque
    Pessac, 33604, France
  • Centre Hospitalier de Saint Quentin
    Saint-Quentin, 02321, France
  • Clinique Sainte Anne
    Strasbourg, 67000, France
  • Institut Universitaire du Cancer Toulouse Oncopole
    Toulouse, 31059, France
  • Klinikum Chemnitz gGmbH
    Chemnitz, 09113, Germany
  • Asklepios Klinik Altona
    Hamburg, 22763, Germany
  • Universitätsklinikum Münster
    Münster, 48149, Germany
  • Universitatsklinikum Tubingen
    Tübingen, 72076, Germany
  • University General Hospital of Evros-Alexandroupolis District
    Alexandroupoli, 68100, Greece
  • General Hospital Evangelismos
    Athens, 10676, Greece
  • Alexandra Hospital
    Athens, 11528, Greece
  • University Hospital of Ioannina
    Ioannina, 45500, Greece
  • General University Hospital of Patras Panagia i Voithia
    Pátrai, 26504, Greece
  • Theagenion Cancer Hospital of Thessaloniki
    Thessaloniki, 54007, Greece
  • General Hospital of Thessaloniki Georgios Papanikolaou
    Thessaloniki, 57010, Greece
  • Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona
    Ancona, 60126, Italy
  • Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
    Brescia, 25123, Italy
  • Azienda Unita Sanitaria Locale LE Presidio Ospedaliero Vito Fazzi Polo Oncologico Giovanni Paolo II
    Lecce, 73100, Italy
  • Policlinico Universitario Agostino Gemelli
    Roma, 00168, Italy
  • Azienda Ospedaliera Citta della Salute e della Scienza di Torino Ospedale Molinette
    Torino, 10126, Italy
  • Hospital Clinico Universitario de Salamanca
    Salamanca, Castille and León 37007, Spain
  • Hospital Universitari Germans Trias i Pujol
    Badalona, Catalonia 08916, Spain
  • Hospital Clinic i Provincial de Barcelona
    Barcelona, Catalonia 08036, Spain
  • Hospital Universitari i Politecnic La Fe
    Valencia, Valencia 46026, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
10

References and documents

Publications

  • Perrot A, Delimpasi S, Spanoudakis E, Frolund U, Belotti A, Oriol A, Moreau P, McFadden I, Xia Q, Arora M, Dimopoulos MA. An open-label phase 2 study treating patients with first or second relapse of multiple myeloma with carfilzomib, pomalidomide, and dexamethasone (KPd): SELECT study. Leuk Lymphoma. 2024 Jun;65(6):833-842. doi: 10.1080/10428194.2024.2322030. Epub 2024 Mar 18. PubMed 38497533 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the link below.

Data sharing details ↗ · www.amgen.com

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2020 to primary completion in Nov 2022, 27 months.

Results were first posted in Nov 2023, 11 months after primary completion.

Of 93 industry-sponsored phase 2 interventional studies under Multiple Myeloma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 77. This study's 27 months is below that.

Counting every sponsor, half of 506 studies reached it within 57 months; a quarter within 35 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 22, 2019
First posted
Dec 10, 2019
StartActual
Aug 6, 2020
Primary completionActual
Nov 30, 2022
CompletionActual
Oct 1, 2024
Results first posted
Nov 8, 2023
Last update
Sep 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT04191616
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Dec 10, 2019
Start date
Aug 6, 2020
Primary completion
Nov 30, 2022
Completion
Oct 1, 2024
Results posted
Nov 8, 2023
Last update
Sep 4, 2025

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Carfilzomib · Dexamethasone · Pomalidomide

Start the discussion